Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Friday.
Several other equities research analysts have also issued reports on the company. Needham & Company LLC upped their price target on Collegium Pharmaceutical from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, December 5th. They noted that the move was a valuation call. HC Wainwright reissued a “buy” rating and set a $21.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, November 17th. Piper Jaffray Companies reissued a “buy” rating and set a $24.00 price target on shares of Collegium Pharmaceutical in a research report on Thursday, December 7th. Jefferies Group upped their price target on Collegium Pharmaceutical to $27.00 and gave the company a “buy” rating in a research report on Tuesday, December 5th. Finally, Zacks Investment Research lowered Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. Collegium Pharmaceutical currently has a consensus rating of “Buy” and a consensus price target of $27.17.
Collegium Pharmaceutical (NASDAQ COLL) opened at $23.91 on Friday. The stock has a market capitalization of $778.56 and a P/E ratio of -8.05. Collegium Pharmaceutical has a 52-week low of $7.37 and a 52-week high of $26.77.
In related news, Chairman Michael Thomas Heffernan sold 20,000 shares of the company’s stock in a transaction on Friday, January 19th. The stock was sold at an average price of $22.50, for a total transaction of $450,000.00. Following the completion of the transaction, the chairman now directly owns 538,987 shares in the company, valued at approximately $12,127,207.50. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Alison B. Fleming sold 6,928 shares of the company’s stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $19.07, for a total value of $132,116.96. Following the transaction, the insider now owns 32,651 shares of the company’s stock, valued at $622,654.57. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,046,928 shares of company stock valued at $18,422,317. 25.76% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Macquarie Group Ltd. grew its stake in Collegium Pharmaceutical by 21.5% during the 4th quarter. Macquarie Group Ltd. now owns 1,616,117 shares of the specialty pharmaceutical company’s stock worth $29,833,000 after buying an additional 286,138 shares during the last quarter. LPL Financial LLC grew its stake in shares of Collegium Pharmaceutical by 6.4% in the fourth quarter. LPL Financial LLC now owns 151,085 shares of the specialty pharmaceutical company’s stock worth $2,789,000 after purchasing an additional 9,082 shares in the last quarter. Teachers Advisors LLC grew its stake in shares of Collegium Pharmaceutical by 11.3% in the fourth quarter. Teachers Advisors LLC now owns 66,533 shares of the specialty pharmaceutical company’s stock worth $1,228,000 after purchasing an additional 6,739 shares in the last quarter. Raymond James & Associates bought a new position in shares of Collegium Pharmaceutical in the fourth quarter worth $389,000. Finally, California State Teachers Retirement System grew its stake in shares of Collegium Pharmaceutical by 10.5% in the fourth quarter. California State Teachers Retirement System now owns 39,499 shares of the specialty pharmaceutical company’s stock worth $729,000 after purchasing an additional 3,752 shares in the last quarter. Hedge funds and other institutional investors own 89.28% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/23/collegium-pharmaceutical-coll-rating-lowered-to-hold-at-bidaskclub.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.